| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 42 | 25.8x | 17.3x | Around median | |
Growth | 63 | 8.6% | 7.1% | Around median | |
Quality | 86 | 14.6% | 4.5% | Top tier | |
Safety | 70 | 1.4x | 2.6x | Top tier | |
Capital Return | 82 | 1.82% | 0.06% | Top tier | |
Momentum | 50 | -1.0% | -1.6% | Around median | |
Sentiment | 93 | 9 | 3 | Top tier |
The floor: what the company is worth if growth stopped today
59% of today's price is what a buyer pays for growth that has not happened yet.
10-year US Treasury yield 4.96% as of 2026-10-22. Estimates computed from company data and analyst targets, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
AstraZeneca PLC develops medicines in oncology, rare diseases, cardiovascular, renal and metabolic diseases, respiratory diseases, and immunology, generating revenue from medicine sales and profit shares in partnered treatments. Its portfolio includes Tagrisso, Calquence and Imfinzi, alongside partnerships for Enhertu, Datroway and Tezspire that contribute alliance revenue when partners record sales. In the 2026-07-27 results presentation, management described oncology and rare diseases as growth drivers, while respiratory and immunology helped offset generic competition affecting Farxiga and Brilinta; its business model therefore combines expanding the use of existing medicines with renewing the portfolio through new treatments.
AstraZeneca recorded revenue of 15.4 billion dollars and net income of 2.5 billion dollars in quarter 2 of fiscal year 2026, ended 2026-06-30, with diluted earnings per share of 1.6 dollars. Gross margin was 83.6% and operating margin was 20.6% in the same period, while operating cash flow was 2.9 billion dollars according to EL7 data. Over the last 12 months through 2026-06-30, revenue totaled 61.4 billion dollars and net income was 10.4 billion dollars, with free cash flow of 8.7 billion dollars according to EL7 data. A reliably comparable year-over-year revenue growth rate is unavailable, so the performance assessment centers on earnings, cash generation and continued renewal of the medicine portfolio.
Q2 FY2026
Last 12 months to 2026-06-30
When: 2026-10-30
Quarterly operating margin at the 20.6% threshold in the expected earnings announcement
Quarterly operating cash flow at the 2.9 billion dollar threshold according to EL7 data in the expected earnings announcement
The discounted cash flow model estimate is 235 dollars, within a range of 181 dollars to 325 dollars, measuring the value of expected cash flows at a discount rate of 8.7% while following analysts' earnings estimates. The industry-multiple value is 204 dollars, within a range of 122 dollars to 227 dollars, based on next year's earnings and a median multiple of 18.0 across 13 companies. The median target from 10 analysts is 185 dollars, within a range of 158 dollars to 216 dollars, reflecting their growth expectations, while the no-growth value is 68 dollars, measuring what remains if current after-tax operating profit stays constant forever at a discount rate of 8.7%. The discounted cash flow, industry-multiple and analyst-target ranges overlap, but the discounted cash flow estimate is higher than the peer-comparison value and the median target, while the low no-growth value illustrates how much the other values depend on continued growth. Analyst targets naturally tend toward optimism and discounted cash flow models toward conservatism across companies, with the ordering of AstraZeneca's specific results differing according to what each method measures and its assumptions.
Figures in the text are as of 2026-10-19; the live price is shown at the top of the page.
AstraZeneca generates revenue from medicine sales and profit shares in partnered treatments, including Enhertu, Datroway and Tezspire in markets where partners record sales. Its total revenue was 15.4 billion dollars in quarter 2 of fiscal year 2026, ended 2026-06-30. On the 2026-07-27 call, management linked oncology strength to demand for Tagrisso and Calquence and expanded uses of Imfinzi and Enhertu. This portfolio is particularly important in offsetting pressure from generics on Farxiga and Brilinta.
According to EL7 data, operating cash flow was approximately 13.8 billion dollars over the last 12 months through 2026-06-30, equivalent to 132% of net income of 10.4 billion dollars. Free cash flow was approximately 8.7 billion dollars for the same period according to EL7 data, supporting the company's ability to fund its activities. In contrast, debt was 32.2 billion dollars against cash and short-term investments of 4.9 billion dollars according to EL7 data in quarter 2 of fiscal year 2026, ended 2026-06-30. This comparison excludes long-term marketable securities and is therefore insufficient on its own to assess overall liquidity.
Automated analysis for informational purposes only — not investment advice.
A 2026-09-28 news report covered a strategic equity investment of 2 billion dollars by AstraZeneca in Summit Therapeutics. The clinical collaboration includes ivonescimab and sonesitatug vedotin, expanding oncology treatment development options. A 2026-10-05 report also covered an agreement with AstraZeneca and Daiichi Sankyo to test ivonescimab with Datroway in breast and lung cancer. These steps are significant for their clinical development opportunities, while generating sales from them remains dependent on study results and the regulatory pathway.
A 2026-10-12 news report stated that the phase 3 HICKORY trial of efzimfotase alfa failed to meet its primary endpoint for treating hypophosphatasia, despite improvements in secondary endpoints. This outcome weakens the clinical case for the program without negating the benefits observed in secondary measures. Management had presented positive results from six major phase 3 programs on the 2026-07-27 call, illustrating the breadth of the portfolio while individual programs remain vulnerable to setbacks. It also acknowledged disappointing CARDIO-TTRansform results on the same call, so the quality of clinical results remains a decisive factor in assessing growth.
The discounted cash flow estimate is 235 dollars, compared with 204 dollars when applying the industry multiple to next year's earnings, because the former measures expected cash flows while the latter compares the company with its peers. The median analyst target is 185 dollars, while the average is 186.67 dollars, with a consensus rated Buy. The no-growth value is 68 dollars because it assumes current after-tax operating profit remains constant forever. This divergence reflects different assumptions about growth, cash flows and peer comparisons, and does not make any of these values a single definitive outcome.